Study on Regeneration of Skin Defects in Diabetic Ulcers Treated With New Electrospun Material PLCL/Fg

Diabetic Foot Clinical Trial

Official title:

Study on Regeneration of Skin Defects in Diabetic Ulcers Treated With New Electrospun Material Poly (L-lactide-co-caprolactone) and Formulated Porcine Fibrinogen

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06014437
• Other study ID #: Jinshan hospital
• Status: Recruiting
• Phase: Phase 4
• Start date: March 1, 2023
• Est. completion date: March 31, 2024

Study information

• Verified date: August 2023
• Source: Fudan University
• Contact: guili wang
• Phone: +8618264188121
• Email: wgl4611[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective cohort studies through clinical trials. Obtained a large amount of real-world data to explore the efficacy of PLCL/Fg dressings for specific clinical applications.

Published 1 relevant SCIE paper. Provide a large amount of data support for the application of PLCL/Fg dressing in diabetic foot ulcer wound repair through basic experimental and clinical experimental studies. It can provide a practical and effective biomaterial for the treatment of clinical skin wound structure and function reconstruction, make the patient's wound healing as soon as possible, benefit the general public, reduce medical expenditure, reduce the burden on the society, lay the foundation for the industrialization and marketization of national innovative medical devices, and help to improve the international status and value of the application.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 52
• Est. completion date: March 31, 2024
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 90 years; type 1 or type 2 diabetes mellitus; history of ulceration for more than 4 weeks at enrollment; wound area between 1 and 25 square centimeters; wound depth of Wagner grades 1 and 2; and an ABI of 0.7 to 1.3 on the affected lower extremity or a transcutaneous oxygen pressure of greater than or equal to 30 mmHg.

Exclusion Criteria:

• Wound healing percentage greater than 30% during wound preparation (7 days); any infection, osteomyelitis, or other condition that may affect wound healing, such as deep vein thrombosis, rheumatoid arthritis, systemic lupus erythematosus, or any other systemic inflammatory disease.

Related Conditions & MeSH terms

• Diabetic Foot

Intervention

Drug:
• PLCL/Fg group
Routine ulcerated wounds were cleaned, and the test group was given an equal-sized PLCL/Fg dressing to cover the wounds.
• control group
Routine ulcerated wounds were cleaned and changed, and the control group was given an alginate dressing of equal size to cover the wounds

Locations

Country	Name	City	State
China	Department of Vascular Surgery, Jinshan Hospital, Fudan University	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Guili Wang

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of complete wound closure during treatment and follow-up (12 weeks). (Outpatient follow-up 2-3 times per week, standardized photographs and measurement of wound size)	Complete healing is defined as complete re-epithelialization of the ulcer bed with no discharge. Speed of healing is calculated by measuring the size or percentage reduction in wound area per week.	12 weeks